CNBC Stock Blog
- Avis on the Road to Strong Growth: Analyst
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- Bulls Check In to Community Health
- Bank of America’s Worst-Case Scenario Gets More Real
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- So Now You Can’t Give Microsoft Away?
ABOUT THE CNBC STOCK BLOG
RSS FEED
CNBC EXPLAINS
This Drugmaker Will Rally by Summer: Investors
Text Size 
writer, OptionMonster
Small-cap drug developer MDRNA reported positive results for an experimental cancer treatment last week, and at least one investor is positioning for a rally by summer.
OptionMonster's real-time systems detected the purchase of about 2,500 June 2.50 calls for $0.10 against open interest of 1,165 contracts. Calls account for all the options activity in the name.
MRNA [MRNA
Loading...
()
] fell 0.98 percent to $1.01 yesterday. The stock traded as high as $1.87 on Jan. 13 after reporting the data on its propriety RNA-interference products. It then lost 23 percent of its value the next day and now seems to be finding support at the $1 level.
MRNA also said it had signed a collaborative agreement with a major drugmaker, which wasn't identified.
The stock needs to rally more than 150 percent by expiration for today's calls to turn a profit. Overall options volume in the name was about 30 times greater than average.
___________________________
MDRNA Competes With:
Johnson & Johnson [JNJ
Loading...
()
]
Novartis [NVS
Loading...
()
]
Procter & Gamble [PG
Loading...
()
]
Eli Lilly [LLY
Loading...
()
]
___________________________
Options Trading School:
___________________________
___________________________
David Russell is a reporter and writer for OptionMonster.
___________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes
